LoginRegister

    Lupin gets USFDA nod to market Tetrabenazine tablets

    Written by Ruby Khatun Khatun   |  


    New Delhi: Drug firm Lupin said it has received approval from the US health regulator to market in America its Tetrabenazine tablets used for the treatment of involuntary movements associated with Huntington's disease.

    The company has received final approval to market the 12.5 mg and 25 mg tablets from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.




    The tablets are generic version of Valeant Pharmaceuticals North America LLC's Xenazine tablets in the same strengths, it added.

    According to IQVIA MAT Jan 2018 data, Tetrabenazine tablets, 12.5 mg, and 25 mg had annual sales of around $288.1 million in the US, Lupin said.

    The product is indicated for the treatment of chorea associated with Huntington's disease, it added.

    approvalfinal approvalgeneric versionHuntington’s diseaseinvoluntary movementsLupinmarketTetrabenazine tabletsUnited States Food and Drug AdministrationUSFDAValeant PharmaceuticalsXenazine tablets
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X